Silence Therapeutics PLC

NASDAQ:SLNUnited States

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

Contact Information

Headquarters

72 Hammersmith RoadLONDON, United Kingdom W14 8TH

Phone

203-457-6900

Fax

795-731-8494

Executives

Non-Executive Chairman of the Board

Iain Ross

President, Chief Executive Officer, Executive Director

Craig Tooman

Chief Technical Operations Officer

J.P Gabriel

Chief Scientific Officer

Marie Lindholm

Chief Medical Officer

Curtis Rambarn